Preladenant + Placebo
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Akathisia, Drug-Induced
Conditions
Akathisia, Drug-Induced, Dyskinesia, Drug-Induced, Parkinsonian Disorders
Trial Timeline
Jul 10, 2006 → Mar 6, 2008
NCT ID
NCT00686699About Preladenant + Placebo
Preladenant + Placebo is a phase 2 stage product being developed by Merck for Akathisia, Drug-Induced. The current trial status is terminated. This product is registered under clinical trial identifier NCT00686699. Target conditions include Akathisia, Drug-Induced, Dyskinesia, Drug-Induced, Parkinsonian Disorders.
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01227265 | Phase 3 | Completed |
| NCT00686699 | Phase 2 | Terminated |
Competing Products
1 competing product in Akathisia, Drug-Induced
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Preladenant + Placebo + Anticholinergic agents or propanolol + Haloperidol | Merck | Phase 2 | 27 |